Comparison

Recombinant Human CD82/KAI-1 Protein (His Tag)

Item no. ELS-PKSH030858-20ug
Manufacturer Elabscience
Amount 20 ug
Quantity options 20 ug 50 ug
Category
Type Proteins
Format Lyophilized Powder
Specific against Human (Homo sapiens)
Host HEK293 cells
Conjugate/Tag HIS
Purity > 90 % as determined by reducing SDS-PAGE.
Sequence Gly 111-Leu 228
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias 4F9, C33, GR15, IA4, KAI-1, KAI1, R2, SAR2, ST6, TSPAN27
Similar products KAI1, SAR2, ST6, TSPAN27, IA4, C33, R2, 4F9, GR15, KAI-1
Shipping Condition Cool pack
Available
Manufacturer - Category
Recombinant Proteins / Others
Manufacturer - Conjugate / Tag
C-His
Shipping Temperature
This product is provided as lyophilized powder which is shipped with ice packs.
Storage Conditions
Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Calculated Molecular Weight
15 kDa
Observed Molecular Weight
25-33 kDa
Research Areas
Immunology, Epigenetics and Nuclear Signaling, Cancer
Background
CD82, also known as KAI-1, structurally belongs to tetraspanin family while categorised as metastasis suppressor gene on functional grounds. KAI1/CD82 is localized on cell membrane and form interactions with other tetraspanins, integrins and chemokines which are respectively responsible for cell migration, adhesion and signalling. Downregulation of CD82 expression is associated with the advanced stages of many human cancers and correlates with the acquisition of metastatic potential. Recent studies suggest that complex mechanisms underlie CD82 loss of function, including altered transcriptional regulation, splice variant production and post-translational protein modifications, and indicate a central role for CD82 in controlling metastasis as a 'molecular facilitator'. The loss of KAI1/CD82 expression in invasive and metastatic cancers is due to a complex, epigenetic mechanism that probably involves transcription factors such as NFkappaB, p53, and beta-catenin. A loss of KAI1 expression is also associated with the advanced stages of many human malignancies and results in the acquisition of invasive and metastatic capabilities by tumour cells. Thus, KAI1/CD82 is regarded as a wide-spectrum tumor metastasis suppressor.
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method.
Reconstitution
Please refer to the printed manual for detailed information.
Formulation
Lyophilized from sterile PBS, pH 7.4
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Activity
Not validated for activity

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 20 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?